Tears Plus

Drug Overview

Tears Plus is a classic, trusted medication within the Ocular Lubricant drug class. For patients dealing with the chronic, gritty, and burning pain of dry eyes, finding a drop that offers reliable, fast-acting relief is a major clinical priority.

Unlike a complex Biologic or an injected VEGF Inhibitor used for deep retinal diseases, this formulation acts as a non-invasive Targeted Therapy for the front of the eye. It is designed to soothe cellular damage, replace missing moisture, and physically protect the delicate outer layers of the cornea from environmental stress and friction.

• Generic Name: Polyvinyl Alcohol (PVA) and Povidone
• US Brand Names: Tears Plus
• Route of Administration: Topical Drops (instilled directly onto the surface of the eye)
• FDA Approval Status: FDA-approved as an Over-The-Counter (OTC) ophthalmic medication for the temporary relief of burning and irritation due to dryness of the eye.

What Is It and How Does It Work? (Mechanism of Action)

Tears Plus utilizes two active polymers, Polyvinyl Alcohol (PVA) and Povidone, to act as artificial mucins and wetting agents. At a physiological level, the cornea is naturally hydrophobic (water-repelling). PVA lowers the surface tension of the eye’s natural tears, allowing the watery portion of the tear film to spread smoothly and evenly across the corneal epithelium rather than beading up and rolling off.

Simultaneously, Povidone provides a lubricating, protective cushion. Together, these polymers bind to the dry patches on the eye, stabilizing the tear film and physically shielding the exposed corneal nerves. By restoring the wetting action of natural tears, this formulation locks in moisture and prevents the cellular dehydration that drives chronic eye inflammation.

FDA-Approved Clinical Indications

Primary Indication

The primary FDA-approved indication for Tears Plus is the symptomatic relief of dry eyes, specifically the temporary relief of burning, irritation, and discomfort due to dryness of the eye.

Other Approved & Off-Label Uses

Ophthalmologists routinely rely on these gentle lubricants for a wide variety of ocular surface conditions requiring consistent management:

• Early-stage Dry Eye Disease (DED)
• Computer Vision Syndrome (Digital Eye Strain)
• Environmental dry eye (due to wind, sun, air conditioning, or dry climates)
• Minor corneal abrasions
• Primary Ophthalmology Indications:
  • Stabilize the Tear Film: By mimicking the natural mucous layer, the drops prevent rapid tear evaporation and break the painful cycle of chronic dryness.
  • Preserve Visual Acuity: A dry, scratched cornea scatters incoming light, causing blurry vision. By smoothing out the optical surface with its polymer blend, these drops help maintain crisp, stable visual acuity.
  • Protect the Epithelial Barrier: Forms a non-toxic, hydrating shield over the cornea, preventing friction from the eyelids from damaging sensitive surface cells during blinking.

Dosage and Administration Protocols

Tears Plus drops are administered topically to the eye. Consistency is vital; using the drops proactively provides far better protection than waiting until the eyes are already burning.

Specific Instructions for Administration: Wash hands thoroughly before use. Tilt the head back, gently pull down the lower eyelid to create a pocket, squeeze the drop in, and close the eye gently. Apply light pressure to the inner corner of the eye (technique for punctal occlusion) for 1 minute to keep the medication on the ocular surface. Wait 5 minutes between different drops if using multiple eye medications. If a patient is using these drops more than 4 times a day, transitioning to a completely Preservative-Free formulation is recommended to avoid cumulative toxicity from the preservatives in the bottle.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

Current clinical study data (2020-2026) strongly supports the use of PVA/Povidone-based lubricants for managing mild to moderate chronic ocular surface disease. In structured trials evaluating dry eye therapies, patients using these polymer blends demonstrate measurable improvements in clinical markers compared to standard saline drops.

Research highlights that Tear Film Break-Up Time (TBUT), a vital clinical test measuring how quickly tears evaporate into the air, frequently increases from an unhealthy baseline of 3 to 4 seconds to a much more stable 6 to 7 seconds. Furthermore, studies utilizing corneal fluorescein staining (which highlights dead or damaged cells) show a 1-grade reduction on the Oxford staining scale, indicating successful epithelial healing. Subjectively, patients report an average 10- to 15-point improvement on the Ocular Surface Disease Index (OSDI) questionnaire. By stabilizing the tear film safely, this therapy is highly efficacious in preventing the long-term corneal micro-abrasions that can eventually impair clear vision.

Safety Profile and Side Effects

There is no “Black Box Warning” for Tears Plus. Because it contains no active pharmacological immunosuppressants or steroids, it boasts an exceptionally high safety profile for the general public.

Common side effects (>10%)

• Blurred Vision: Mild, temporary blurring immediately upon instillation as the polymer network forms over the cornea (usually clears within 30 to 60 seconds).
• Sticky Eyelashes: A minor, harmless residue left on the eyelid margins after the drops dry.

Serious adverse events

• Microbial Keratitis: A serious bacterial or fungal eye infection, typically caused by touching the dropper tip to a dirty surface, the eyelashes, or the eye itself, thereby contaminating the bottle.
• Allergic Conjunctivitis: Hypersensitivity to the inactive ingredients or the chemical preservatives (like BAK), leading to chronic redness, itching, and swelling.

Management Strategies: To minimize the risk of microbial keratitis, patients must practice strict sterile administration techniques. If a patient experiences a stinging or allergic reaction to the preservative, management involves immediately switching to a Preservative-Free alternative.

Research Areas

Direct Clinical Connections: Current ophthalmology research heavily focuses on how artificial mucins protect goblet cell density. Goblet cells in the conjunctiva produce the vital natural mucous layer of the tear film. Studies prove that reducing the hyperosmolarity (saltiness) of the tear film protects these goblet cells from undergoing cellular death. By utilizing advanced lubricating drops, patients actively promote the eye’s natural ability to produce healthy tears.

Generalization: Between 2020 and 2026, the global industry has seen a massive shift toward advanced Novel Delivery Systems. Research is actively focused on multi-dose Preservative-Free bottles equipped with advanced internal filtration systems. This technology allows patients to avoid chemical preservatives entirely while reducing plastic waste.

Severe Disease & Surgical Integration: In severe disease, simple artificial tears are often researched as essential baseline therapies used alongside prescription anti-inflammatories to prevent blindness in severe Sjögren’s Syndrome or as an adjunct following corneal transplants.

Disclaimer: These studies regarding new multi-dose filtration technologies and advanced surgical integrations are currently in the preclinical or early clinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: Comprehensive measurement of Baseline Visual Acuity, Tonometry (IOP measurement) to rule out high eye pressure as a cause of eye pain, and a detailed Slit-lamp exam to evaluate the health of the cornea and eyelids.
• Ocular Imaging: Optical Coherence Tomography (OCT) of the anterior segment can be utilized to measure the tear meniscus height, confirming the true volume of tears.
• Specialized Testing: Corneal topography to check for irregular astigmatism caused by dryness, tear film break-up time (TBUT) using fluorescein dye, and meibomian gland evaluation.
• Screening: A thorough history of previous ocular surgeries (like LASIK), underlying autoimmune diseases, or known allergies to generic eye drop preservatives.

Monitoring and Precautions

• Vigilance: Patients should be monitored to ensure dry eye is not worsening despite frequent lubrication. If a patient is taking concurrent topical steroids for inflammation, monitoring for “rebound” inflammation or sudden spikes in IOP following steroid use is mandatory.
• Lifestyle: Environmental modifications are crucial for long-term success. Patients must wear UV protection (sunglasses) outdoors, utilize humidifiers in dry environments, and manage blue light exposure. Practicing the “20-20-20 rule” (looking 20 feet away for 20 seconds every 20 minutes) during screen time encourages healthy blinking. Routine eyelid hygiene (lid scrubs) and dietary supplements (such as Omega-3 fatty acids) heavily support overall ocular health.

“Do’s and Don’ts” list

• DO wash your hands thoroughly with soap and water before handling your eye drops.
• DO gently press on the inner corner of your eye after inserting the drop to keep the medication on the eye longer.
• DO store your eye drops at room temperature and keep the cap tightly closed.
• DON’T let the tip of the bottle touch your eye, eyelashes, fingers, or any other surface.
• DON’T use the drops if the liquid changes color, becomes cloudy, or if the expiration date has passed.
• DON’T ignore worsening eye pain or severely decreased vision; contact your ophthalmologist immediately.

Legal Disclaimer

The medical information provided in this comprehensive guide is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Mild dry eye symptoms can occasionally mimic more serious, vision-threatening conditions. Always seek the advice of your ophthalmologist, optometrist, or other qualified healthcare provider regarding your specific eye health, and before starting, stopping, or changing any treatment regimen. Never disregard professional medical advice or delay seeking it because of information contained in this material.